Brief: Transgene Updates On TG4050 Phase I Trial

Transgene SA

28/06/2021 06:07

June 28 (Reuters) - Transgene SA  TRNG.PA :
    * FIRST HEAD & NECK CANCER PATIENT ENROLLED IN THE UK IN A PHASE I TRIAL
WITH
TG4050 (MYVAC® PLATFORM), TRANSGENE’S INNOVATIVE INDIVIDUALIZED IMMUNOTHERAPY
    * FIRST DATA FROM TWO ONGOING CLINICAL TRIALS EXPECTED IN 4Q 2021

Source text for Eikon:  ID:nBw7j1P75a 
Further company coverage:  TRNG.PA 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))